drugset
drugset / Trial / NCT04730895

Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.

NCT04730895 ↗

Phase 1/2 Unknown 360 enrolled Kafrelsheikh University
RandomizedParallel-groupOpen-labelPrevention

Summary

Investigating the role of 13cis retinoic acid in the treatment of COVID-19 and enhancement of Its spike protein based vaccine efficacy and safety.

Timeline

Start
2021-07
Primary completion
2021-09
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator ChAdOx1 nCoV-19 vaccine Vaccine 5e+10 unknown —
Comparator ChAdOx1 nCoV-19 vaccine Vaccine 7.5e+10 unknown —
Subject Isotretinoin Other / unclassified 0.5 mg/kg Oral
Subject Isotretinoin Other / unclassified 4 mg/kg Oral

Indications

No indication recorded.